BioVersys AG Balance Sheet

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	92.07	26.62	24.38
Short-Term Investments	-	6	4
Cash & Short-Term Investments	92.07	32.62	28.38
Cash Growth	-	14.95%	-
Other Receivables	-	1.29	2.07
Receivables	-	1.29	2.07
Prepaid Expenses	2.21	0.49	0.3
Other Current Assets	-	-	2.85
Total Current Assets	94.28	34.4	33.59
Property, Plant & Equipment	0.44	0.56	0.58
Total Assets	94.72	34.96	34.17
Accounts Payable	0.78	0.71	1.29
Accrued Expenses	2.88	3.45	2.2
Current Portion of Long-Term Debt	4.01	2.98	0.03
Current Portion of Leases	0.23	0.22	0.22
Current Unearned Revenue	-	1.15	1.07
Other Current Liabilities	2.31	1.17	4.55
Total Current Liabilities	10.21	9.67	9.37
Long-Term Debt	13.99	13.63	15.55
Long-Term Leases	0.02	0.13	0.13
Total Liabilities	24.85	24.27	25.59
Common Stock	5.84	3.69	3.06
Additional Paid-In Capital	155.6	87.4	68.77
Retained Earnings	-90.95	-80.34	-62.94
Comprehensive Income & Other	-0.62	-0.07	-0.32
Shareholders' Equity	69.88	10.68	8.58
Total Liabilities & Equity	94.72	34.96	34.17
Total Debt	18.25	16.97	15.93
Net Cash (Debt)	73.82	15.65	12.45
Net Cash Growth	-	25.77%	-
Net Cash Per Share	16.56	4.70	4.17
Filing Date Shares Outstanding	5.84	5.82	2.99
Total Common Shares Outstanding	5.84	0.33	2.99
Working Capital	84.08	24.73	24.22
Book Value Per Share	11.97	32.50	2.87
Tangible Book Value	69.88	10.68	8.58
Tangible Book Value Per Share	11.97	32.50	2.87
Machinery	-	0.58	0.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.